By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
The panelists generally agree that ResMed's valuation is influenced by GLP-1 drug adoption and its impact on the sleep apnea market. While some believe the market is overreacting to GLP-1 fears, others argue that the potential reduction in new diagnoses and changes in clinical efficacy could significantly impact ResMed's total addressable market and revenue growth.
Risk: Contraction of the total addressable market due to GLP-1 drugs reducing the severity of sleep apnea or delaying CPAP adoption.
Opportunity: Re-rating of ResMed's valuation towards historical multiples as GLP-1 adoption matures and data confirms the continued necessity of CPAP for most patients.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Is RMD a good stock to buy? We came across a bullish thesis on ResMed Inc. on r/investing_discussion by Variant_Invest. In this article, we will summarize the bulls’ thesis on RMD. ResMed Inc.'s share was trading at $196.94 as of June 9th. RMD’s trailing and forward P/E were 18.99 and 16.61 respectively according to Yahoo Finance.
Billion Photos/Shutterstock.com
ResMed is a leading global sleep apnea treatment company that the market has recently mispriced due to fears around GLP-1 weight-loss drugs disrupting its core therapy demand. Despite the narrative, ResMed continues to operate in a structural demand market with an estimated 936 million sleep apnea patients globally, a base that is unlikely to be meaningfully reduced in the foreseeable future.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
The company’s core strength lies in its consumables business, where masks, tubes and headgear are replaced every ninety days under insurance reimbursement cycles, creating highly predictable and recurring revenue streams. This segment generates gross margins above 60 percent and remains resilient because the underlying condition is anatomical, meaning even patients using GLP-1 drugs often still require CPAP therapy for residual apnea.
ResMed’s AirView connected care platform further strengthens its moat, linking approximately twenty two million devices and providing payers with compliance data that reduces hospitalizations and improves care efficiency across the ecosystem. The increasing scale of this data network enhances switching costs and embeds ResMed deeper into payer and provider workflows, reinforcing long-term recurring revenue visibility.
Financially, ResMed generates approximately 2.2 billion dollars in annual free cash flow, reflecting the durability of its model and strong operating leverage. Despite this strength, the stock has been under pressure for two years due to GLP-1 driven concerns that have not been reflected in actual fundamentals. At current levels, ResMed trades at a discount to its historical 30x-plus quality multiple, offering a compelling long-term re-rating opportunity as fears normalize over time unwinds.
Previously, we covered a bullish thesis on ResMed Inc. (RMD) by LongTermValue Research in April 2025, which highlighted the company’s strong sleep apnea demand and growth outlook. RMD’s stock price has depreciated by approximately 11.68% since our coverage. Variant_Invest shares a similar view but emphasizes GLP-1 fears as overblown and highlights consumables and AirView data platform as key recurring revenue and moat drivers supporting long-term compounding.
Four leading AI models discuss this article
"RMD's bullish case hinges on unproven resilience of demand and multiples without addressing potential volume erosion from GLP-1 therapies."
The article positions RMD as undervalued at 16.61x forward P/E due to overstated GLP-1 disruption risks, citing 936 million global apnea patients, 60%+ gross margins on recurring consumables, $2.2B FCF, and the AirView platform's data moat. Yet it provides no quantitative evidence on how much apnea severity actually declines with GLP-1 use or whether payers will adjust reimbursement cycles. The 11.68% post-April decline suggests the market is pricing in more than narrative fear. Without clinical volume data or competitive response details, the re-rating thesis to 30x rests on assumptions that may not hold if obesity treatment adoption accelerates.
Even if anatomical factors persist, large-scale weight loss could cut moderate-to-severe cases enough to shrink the addressable market and slow mask replacement cycles, undermining both growth and the historical multiple.
"GLP-1 adoption and payer dynamics pose a material, underappreciated risk to ResMed’s near-term growth and margin trajectory, potentially compressing the valuation."
ResMed shows durability in its consumables moat and AirView data network, with high gross margins and strong free cash flow. But the strongest case against the obvious bullish read is that GLP-1 obesity drugs could shrink the diagnosed sleep apnea population or delay CPAP adoption more than expected, risking slower revenue growth and multiple compression. The article glosses over potential reimbursement headwinds, price pressure on consumables, competition in masks, and regulatory/data-privacy risk around AirView. Missing context includes the sensitivity of RMD’s revenue to obesity trend shifts, actual penetration of AirView monetization, and policy changes that could hit margins.
Bull case: GLP-1 disruption may be milder than feared, and ResMed’s AirView moat plus recurring consumables revenue can sustain growth and justify the multiple even if near-term headwinds persist.
"The market is incorrectly discounting ResMed as a hardware company rather than a high-margin, recurring-revenue data ecosystem, creating a structural entry point."
ResMed (RMD) is currently mispriced, trading at a forward P/E of 16.6x against a historical 30x multiple, largely due to irrational GLP-1 anxiety. The market is conflating weight loss with a cure for obstructive sleep apnea (OSA), ignoring that OSA is frequently structural/anatomical. With 22 million connected devices on AirView, ResMed has built a high-moat, recurring revenue engine that is essentially a 'software-as-a-medical-device' play. The 60%+ gross margins on consumables provide a durable floor for cash flow. As GLP-1 adoption matures and data confirms that CPAP compliance remains necessary for most patients, we should see a significant valuation re-rating toward the 20-22x range.
The bear case is that GLP-1s aren't just a temporary fear but a long-term secular threat to the 'new patient' pipeline, and the 30x historical multiple was a bubble era anomaly that will never return.
"RMD's bull case requires proof that device sales and consumables attach rates are stable or growing in the GLP-1 era, which the article asserts but does not demonstrate with recent quarterly data."
RMD's valuation case hinges on two claims: (1) GLP-1 fears are overblown, and (2) consumables + AirView moat justify re-rating to 30x+ forward multiples. The first is testable—Q2/Q3 earnings will show if CPAP device sales and mask attach rates are actually holding. The second is speculative. At 16.61x forward P/E, RMD is cheap *if* earnings growth accelerates and the market re-rates it. But the article provides no forward growth rate, no guidance, no recent quarter-over-quarter trends. We're asked to believe in a re-rating without evidence the underlying business is re-accelerating. The $2.2B FCF is real, but FCF yield at current price isn't disclosed. AirView's 22M devices is impressive but doesn't automatically translate to pricing power or margin expansion.
If GLP-1 adoption continues climbing and even 10-15% of CPAP patients achieve sufficient weight loss to reduce apnea severity, RMD's consumables replacement cycle could compress materially—and the article offers zero data on actual patient discontinuation rates or mask replacement trends post-GLP-1 launch.
"Re-rating requires stable diagnosis volumes, not just retention of existing patients."
Claude rightly notes the absence of forward growth evidence, but the bigger gap is upstream: nobody quantified how GLP-1s might reduce new OSA diagnoses via lower screening referrals from primary care. Gemini's 20-22x re-rating assumes the funnel stays intact once fears fade, yet if obesity drugs cut moderate-severe cases by even 8-12%, attach rates and replacement cycles compress before AirView data can offset it.
"GLP-1 adoption could shrink new OSA diagnoses by 5-10% over 2-3 years, compressing CPAP growth and undermining the re-rating thesis despite AirView."
While the upstream gap Grok highlights is real, the missing piece is quantifying GLP-1's impact on new OSA diagnoses and primary-care referrals. If GLP-1 adoption trims new OSA diagnoses by, say, 5-10% over 2-3 years, the growth runway for CPAP devices and mask attach could flatten or decline, eroding the rationale for a re-rating even with AirView and consumables moat. AirView monetization aside, market size risk matters more than discussed.
"GLP-1 induced weight loss clinically reduces OSA severity, directly threatening the medical necessity and long-term retention of the current CPAP patient base."
Gemini’s assumption that OSA is purely structural ignores that 70% of OSA patients are obese; weight loss directly reduces the AHI (Apnea-Hypopnea Index) score, moving patients from 'severe' to 'mild' or 'none.' This isn't just a referral funnel issue; it’s a clinical efficacy issue. If GLP-1s lower AHI thresholds, the 'medical necessity' for CPAP evaporates for a massive segment of the installed base. We are debating market share when we should be debating total addressable market contraction.
"Clinical improvement ≠ market exit; RMD's real risk is mask attach/replacement cycles compressing, not wholesale CPAP abandonment."
Gemini conflates clinical efficacy with market behavior. Yes, GLP-1s lower AHI scores—that's biochemistry. But the market question is: how many patients *discontinue* CPAP vs. reduce mask replacement frequency? AirView data should answer this by Q3. The TAM contraction thesis requires evidence that patients achieving normal AHI actually stop therapy, not just use masks less often. That's a behavioral/compliance question, not a clinical one.
The panelists generally agree that ResMed's valuation is influenced by GLP-1 drug adoption and its impact on the sleep apnea market. While some believe the market is overreacting to GLP-1 fears, others argue that the potential reduction in new diagnoses and changes in clinical efficacy could significantly impact ResMed's total addressable market and revenue growth.
Re-rating of ResMed's valuation towards historical multiples as GLP-1 adoption matures and data confirms the continued necessity of CPAP for most patients.
Contraction of the total addressable market due to GLP-1 drugs reducing the severity of sleep apnea or delaying CPAP adoption.